Adamis Pharmaceuticals Corporation – NASDAQ:ADMP

Add to watchlist

Market open

Closed in about 4 hours

-43.02%

month

-62.56%

quarter

+138.46%

year

Market Cap	7.25M
Enterprise value	13.37M

P/E	-0.52
EV/Sales	2.24
EV/EBITDA	-0.31
Price/Sales	2.37
Price/Book	-17.46
PEG ratio	-0.01
EPS	-4.84

Revenue	12.67M
EBITDA	-15.98M
Income	-11.55M
Revenue Q/Q	501.85%
Revenue Y/Y	722.57%

Profit margin	-755.43%
Oper. margin	-691.51%
Gross margin	-40.16%
EBIT margin	-691.51%
EBITDA margin	-126.14%

Get more financial ratios!

Every financial ratio you might need
10 years history
Forward ratios (Analysts estimates)

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Adamis Pharmaceuticals Corporation (NASDAQ:ADMP): Profit margin
Dec 2022	2.15M	-3.40M	-158.23%
Mar 2023	1.45M	71.70K	4.93%
Jun 2023	6.94K	-8.57M	-123457.48%
Sep 2023	9.06M	348.20K	3.84%

Adamis Pharmaceuticals Corporation (NASDAQ:ADMP): Debt to assets
Dec 2022	10930840	11.73M	107.39%
Mar 2023	9076095	18.75M	206.67%
Jun 2023	4749150	16.57M	349%
Sep 2023	8957411000	13.92B	155.42%

Adamis Pharmaceuticals Corporation (NASDAQ:ADMP): Cash Flow
Dec 2022	-1.52M	155.30K	284.71M
Mar 2023	-1.54M	841.77K	2.72M
Jun 2023	-2.56M	138.29K	750
Sep 2023	0	0	0

Adamis Pharmaceuticals alternative data

Social Media

🎓 Academy: How impactful can social media data be in investment decisions

Adamis Pharmaceuticals
Employees

Adamis Pharmaceuticals Corporation (NASDAQ:ADMP): Employee count
Aug 2023	11
Sep 2023	11
Oct 2023	11
Nov 2023	11
Dec 2023	11
Jan 2024	11
Feb 2024	11
Mar 2024	11
Apr 2024	11
May 2024	11
Jun 2024	11
Jul 2024	11

Adamis Pharmaceuticals
Hedge Funds Holdings Q1 2022

9.98% -0.97%

of ADMP is owned by hedge funds

43 -5

hedge funds hold ADMP stock

12.92M -1.25M

shares is hold by hedge funds

ADMP hedge funds holdings changes

Adamis Pharmaceuticals
Insider Trading

Adamis Pharmaceuticals Corporation (NASDAQ:ADMP): Insider trades (number of shares)
Period	Buy	Sel
Dec 2021	0	147734
Mar 2022	0	34151

Transaction	Date	Insider	Security	Shares	Price per share	Total value
Option	25 May 2022	CARLO DENNIS J PHD other: Former Pre..	Restricted Stock Units	250,000	N/A	N/A
Option	25 May 2022	CARLO DENNIS J PHD other: Former Pre..	Common Stock	250,000	N/A	N/A
Sale	18 Mar 2022	MOSS RONALD B. officer: Chief Me..	Common Stock	8,199	$0.6	$4,952
Sale	18 Mar 2022	CARLO DENNIS J PHD director, officer..	Common Stock	10,490	$0.6	$6,284
Sale	18 Mar 2022	MARGUGLIO DAVID J. director, officer: SVP and Chief Busine.. director, officer: SVP and Chie..	Common Stock	11,859	$0.6	$7,115
Sale	18 Mar 2022	BENEDICTO DAVID C. officer: Chief Financial Officer officer: Chief Financial Officer	Common Stock	3,603	$0.61	$2,209
Sale	1 Dec 2021	CARLO DENNIS J PHD director, officer..	Common Stock	47,870	$0.79	$37,578
Sale	1 Dec 2021	MARGUGLIO DAVID J. director, officer: SVP and Chief Busine.. director, officer: SVP and Chie..	Common Stock	50,757	$0.79	$39,844
Sale	1 Dec 2021	MOSS RONALD B. officer: Chief Me..	Common Stock	35,553	$0.79	$27,909
Sale	1 Dec 2021	BENEDICTO DAVID C. officer: Chief Financial Officer officer: Chief Financial Officer	Common Stock	13,554	$0.79	$10,640

ADMP insider trading transactions

Adamis Pharmaceuticals
Patents

Status	Patent	Filling date	Issue date
Application	Application Formulation Including a Combination of beta-Endorphin and Adrenocorticotropic Hormone Filling date: 18 Feb 2022 Issue date: 4 Aug 2022	18 Feb 2022	4 Aug 2022
Grant	Grant Utility: Formulation including a combination of beta-endorphin and adrenocorticotropic hormone Filling date: 31 Aug 2020 Issue date: 29 Mar 2022	31 Aug 2020	29 Mar 2022
Application	Application Formulation Including a Combination of beta-Endorphin and Adrenocorticotropic Hormone Filling date: 13 Mar 2020 Issue date: 24 Feb 2022	13 Mar 2020	24 Feb 2022
Application	Application SYRINGE DEVICES Filling date: 7 Oct 2021 Issue date: 27 Jan 2022	7 Oct 2021	27 Jan 2022
Application	Application DRUG COMPOSITIONS Filling date: 1 Nov 2019 Issue date: 6 Jan 2022	1 Nov 2019	6 Jan 2022
Grant	Grant Utility: Syringe devices Filling date: 17 Mar 2016 Issue date: 12 Oct 2021	17 Mar 2016	12 Oct 2021
Application	Application EMERGENCY DEVICES Filling date: 7 Jun 2021 Issue date: 23 Sep 2021	7 Jun 2021	23 Sep 2021
Application	Application DRUG COMPOSITIONS Filling date: 14 May 2021 Issue date: 2 Sep 2021	14 May 2021	2 Sep 2021
Application	Application DRUG COMPOSITIONS Filling date: 7 Dec 2018 Issue date: 8 Jul 2021	7 Dec 2018	8 Jul 2021
Grant	Grant Utility: Drug compositions Filling date: 4 Sep 2019 Issue date: 29 Jun 2021	4 Sep 2019	29 Jun 2021

ADMP patents

Adamis Pharmaceuticals
Earnings Call Transcripts

Quarter	Transcript
Q1 2023 15 May 2023	Q1 2023 Earnings Call Transcript
Q4 2022 17 Mar 2023	Q4 2022 Earnings Call Transcript
Q3 2022 14 Nov 2022	Q3 2022 Earnings Call Transcript
Q2 2022 11 Aug 2022	Q2 2022 Earnings Call Transcript

ADMP earnings call transcripts

Adamis Pharmaceuticals
Executives

Insider	Age	Since	Compensation
Dr. Dennis J. Carlo (1943) Pres, Chief Executive Officer & Director	82		$982,810
Dr. Ronald B. Moss (1961) Chief Medical Officer	64		$613,650

Adamis Pharmaceuticals
Latest News

Thursday, 7 September 2023
12:00	Adamis Pharmaceuticals Changes Name to DMK Pharmaceuticals to Reflect New Strategic Focus	globenewswire.com
Monday, 21 August 2023
09:15	Adamis Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Corporate Update	globenewswire.com
Friday, 4 August 2023
13:43	Adamis Pharmaceuticals Announces Closing of $8.0 Million Public Offering	globenewswire.com
Wednesday, 2 August 2023
08:30	Adamis Pharmaceuticals Announces Pricing of $8.0 Million Public Offering	globenewswire.com
Friday, 28 July 2023
08:30	Adamis Pharmaceuticals to Fund ZIMHI® Clinical Study with University of Leiden Opioid Expert	globenewswire.com
Monday, 26 June 2023
07:30	Adamis Pharmaceuticals Announces NIH Grant Funding for the Treatment of Alcohol Use Disorder	globenewswire.com
Thursday, 22 June 2023
07:30	Adamis Pharmaceuticals Participated in White House Meeting Regarding Opioid Overdose Prevention	globenewswire.com
Thursday, 25 May 2023
16:26	Adamis Pharmaceuticals Announces Closing of the Merger with DMK Pharmaceuticals	globenewswire.com
Friday, 19 May 2023
12:00	Adamis Pharmaceuticals Announces Reverse Stock Split	globenewswire.com
Monday, 15 May 2023
18:32	Adamis Pharmaceuticals Corporation (ADMP) Q1 2023 Earnings Call Transcript	Seeking Alpha
Friday, 17 March 2023
16:50	Adamis Pharmaceuticals Corporation (ADMP) Q4 2022 Earnings Call Transcript	Seeking Alpha
Tuesday, 14 March 2023
16:01	Adamis Pharmaceuticals Schedules Fourth Quarter and Full Year 2022 Financial Results Conference Call and Corporate Update	GlobeNewsWire
Tuesday, 28 February 2023
10:45	Adamis Pharmaceuticals (ADMP) Stock Wavers on Merger News	InvestorPlace
Sunday, 12 February 2023
11:00	How to Diversify Your Penny Stock Investments	PennyStocks
Monday, 14 November 2022
22:03	Adamis Pharmaceuticals Corporation (ADMP) Q3 2022 Earnings Call Transcript	Seeking Alpha
Friday, 21 October 2022
13:27	10 Top Penny Stocks To Buy For Uner $1 Right Now	PennyStocks
Thursday, 20 October 2022
14:28	Good Penny Stocks To Buy Now? 7 Under $1 To Watch This Week	PennyStocks
Friday, 30 September 2022
15:14	Adamis Pharmaceuticals: Managing A Position In A Company Diagnosed With Chronic Failure	Seeking Alpha
Thursday, 11 August 2022
19:00	Adamis Pharmaceuticals Corporation (ADMP) CEO David J. Marguglio on Q2 2022 Results - Earnings Call Transcript	Seeking Alpha
Monday, 8 August 2022
07:30	Adamis Pharmaceuticals Schedules Second Quarter 2022 Financial Results Conference Call and Corporate Update	GlobeNewsWire
Sunday, 31 July 2022
11:30	What to Look For in a Penny Stock in 2022	PennyStocks
Tuesday, 31 May 2022
13:33	What Makes Adamis (ADMP) a New Buy Stock	Zacks Investment Research
Monday, 16 May 2022
21:28	Adamis Pharmaceuticals Corporation (ADMP) CEO Dennis Carlo on Q1 2022 Results - Earnings Call Transcript	Seeking Alpha
Monday, 9 May 2022
17:56	Adamis Pharmaceuticals Schedules First Quarter 2022 Financial Results Conference Call and Business Update	GlobeNewsWire
09:03	5 Winning Stocks to Land on the Overlooked Rising P/E Trick	Zacks Investment Research
Thursday, 31 March 2022
19:20	Adamis Pharmaceuticals Corporation (ADMP) CEO Dr. Dennis Carlo on Q4 2021 Results - Earnings Call Transcript	Seeking Alpha
Thursday, 24 March 2022
07:30	Adamis Pharmaceuticals Schedules Fourth Quarter and Full Year 2021 Financial Results Conference Call and Business Update	GlobeNewsWire
Tuesday, 22 March 2022
09:33	Adamis Pharma Recalls Allergy Treatment Symjepi For Potential Manufacturing Defect	Benzinga
Thursday, 20 January 2022
12:20	Adamis Pharmaceuticals: Market Continues To Overlook TEMPOL's Potential To Be A Leading COVID-19 Therapeutic	Seeking Alpha
Monday, 10 January 2022
15:13	3 Penny Stocks to Watch With the Stock Market Down Today	PennyStocks

Frequently Asked Questions (FAQ)

When is Adamis Pharmaceuticals's next earnings date?

Unfortunately, Adamis Pharmaceuticals's (ADMP) next earnings date is currently unknown.
Does Adamis Pharmaceuticals pay dividends?

No, Adamis Pharmaceuticals does not pay dividends.
How much money does Adamis Pharmaceuticals make?

Adamis Pharmaceuticals has a market capitalization of 7.25M and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 115.34% to 4.76M US dollars.
What is Adamis Pharmaceuticals's stock symbol?

Adamis Pharmaceuticals Corporation is traded on the NASDAQ under the ticker symbol "ADMP".
What is Adamis Pharmaceuticals's primary industry?

Company operates in the Healthcare sector and Drug Manufacturers - Specialty & Generic industry.
How do i buy shares of Adamis Pharmaceuticals?

Shares of Adamis Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Who are Adamis Pharmaceuticals's key executives?
Adamis Pharmaceuticals's management team includes the following people:
- Dr. Dennis J. Carlo Pres, Chief Executive Officer & Director(age: 82, pay: $982,810)
- Dr. Ronald B. Moss Chief Medical Officer(age: 64, pay: $613,650)
How many employees does Adamis Pharmaceuticals have?

As Jul 2024, Adamis Pharmaceuticals employs 11 workers.
When Adamis Pharmaceuticals went public?

Adamis Pharmaceuticals Corporation is publicly traded company for more then 30 years since IPO on 14 Aug 1995.
What is Adamis Pharmaceuticals's official website?

The official website for Adamis Pharmaceuticals is adamispharmaceuticals.com.
Where are Adamis Pharmaceuticals's headquarters?

Adamis Pharmaceuticals is headquartered at 11682 El Camino Real, San Diego, CA.
How can i contact Adamis Pharmaceuticals?

Adamis Pharmaceuticals's mailing address is 11682 El Camino Real, San Diego, CA and company can be reached via phone at 858 997 2400.

Adamis Pharmaceuticals Corporation

adamispharmaceuticals.com

Exchange:

NASDAQ

Full time employees:

Industry:

Drug Manufacturers - Specialty & Generic

Sector:

Healthcare

Adamis Pharmaceuticals Corporation, a specialty biopharmaceutical company, develops and commercializes products in the therapeutic areas of allergy, opioid overdose, respiratory, and inflammatory disease in the United States. The company's product candidates comprise SYMJEPI epinephrine pre-filled syringe injectable products for use in the emergency treatment of acute allergic reactions, including anaphylaxis; dry powder inhaler products for the treatment of asthma; and naloxone injection for the treatment of opioid overdose. It also offers APC400, a tempol gel use of reducing radiation dermatitis in patients undergoing treatment for cancer; and APC410 for the treatment of respiratory diseases, including asthma, respiratory syncytial virus, influenza, and COVID-19. In addition, the company provides corticosteroids, hormone replacement therapies, hospital outsourcing products, and injectables; and veterinary pharmaceutical products for animals. Adamis Pharmaceuticals Corporation was founded in 2006 and is headquartered in San Diego, California.

858 997 2400

11682 El Camino Real
San Diego, CA 92130

CIK: 0000887247
ISIN: US00547W2089
CUSIP: 00547W208